FrancophonIA/ELRC3.0 huggingface dataset:
English: How does Tagrisso work?
Estonian: Kuidas Tagrisso toimib?
English: It contains the active substance osimertinib.
Estonian: Ravim sisaldab toimeainena osimertiniibi.
English: Tagrisso has been shown in studies to be effective at shrinking tumors in patients with these mutations and at slowing down the worsening of the cancer.
Estonian: Tagrisso on osutunud uuringutes efektiivseks kasvaja suuruse vähendamisel nende mutatsioonidega patsientidel ja vähi süvenemise aeglustamisel.
English: Tagrisso must not be used together with St. John's wort (a herbal preparation used to treat depression).
Estonian: Tagrissot ei tohi kasutada koos naistepunaga (taimne depressiooniravim).
English: What benefits of Tagrisso have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Tagrisso kasulikkus?
English: How is Tagrisso used?
Estonian: Kuidas Tagrissot kasutatakse?
English: An overview of Tagrisso and why it is authorised in the EU
Estonian: Ülevaade ravimist Tagrisso ja ELis müügiloa väljastamise põhjendus
English: Tagrisso has been shown to be effective at shrinking tumours in patients with NSCLC and at slowing down the worsening of the cancer.
Estonian: Tagrisso puhul on tõendatud efektiivsus mitteväikerakulise kopsuvähiga patsientidel kasvaja suuruse vähendamisel ja vähi süvenemise aeglustamisel.
English: Tagrisso is medicine for treating a lung cancer called non-small cell lung cancer (NSCLC) when the cancer is advanced or has spread.
Estonian: Tagrisso on kaugelearenenud või levinud mitteväikerakulise kopsuvähi raviks kasutatav ravim.
English: The results were as follows:
Estonian: Tulemused olid järgmised:
English: Further information on Steglatro can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Lisateave Steglatro kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: What measures are being taken to ensure the safe and effective use of Steglatro?
Estonian: Mis meetmed võetakse, et tagada Steglatro ohutu ja efektiivne kasutamine?
English: The patient should start with one 5 mg tablet once a day in the morning.
Estonian: Ravi peab alustama annusega üks 5 mg tablett üks kord ööpäevas hommikuti.
English: Steglatro is available as tablets (5 and 15mg).
Estonian: Steglatrot turustatakse tablettidena (5 ja 15 mg).
English: The European Medicines Agency concluded that Steglatro‘s benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Steglatro kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise saab Euroopa Liidus heaks kiita.
English: As for all medicines, data on the use of Steglatro is continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Steglatro kasutamise kohta pidevat järelvalvet.
English: If the patients' glucose level is still too high the dose can be increased to 15 mg once a day.
Estonian: Kui patsiendi vere glükoosisisaldus on ikka liiga suur, võib annust suurendada kuni 15 mg-ni üks kord ööpäevas.
English: Steglatro (ertugliflozin)
Estonian: Steglatro (ertugliflosiin)
English: The most common side effects with Steglatro (which may affect more than 1 in 10 people) are fungal infections of the vagina and other infections of the female reproductive system.
Estonian: Steglatro kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on tupe seeninfektsioonid ja naiste reproduktiivsüsteemi muud infektsioonid.
English: Type 2 diabetes is a disease in which the body does not make enough insulin to control the level of glucose in the blood or when the body is unable to use insulin effectively.
Estonian: II tüüpi diabeet on haigus, mille korral organism ei tooda vere glükoosisisalduse reguleerimiseks piisavalt insuliini või organism ei suuda insuliini efektiivselt kasutada.
English: The data from this study showed that the effect of ertugliflozin reduces when the kidneys do not work properly.
Estonian: Selle uuringu andmed näitasid, et ertugliflosiini toime väheneb, kui neerud ei tööta õigesti.
English: Side effects reported with Steglatro are carefully evaluated and any necessary action taken to protect patients.
Estonian: Steglatro kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: At the start of the studies, patients' HbA1c was above 7 percentage points.
Estonian: Uuringu alguses oli patsientide HbA1c sisaldus üle 7%.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Steglatro have been included in the summary of product characteristics and the package leaflet.
Estonian: Steglatro ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Steglatro is not as effective in patients with moderate kidney impairment and should therefore not be started in such patients.
Estonian: Steglatro ei ole mõõduka neerufunktsiooni kahjustusega patsientidel nii efektiivne, mistõttu ei tohi seda ravi nendel patsientidel alustada.
English: For more information about using Steglatro, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Steglatroga kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: Steglatro can be used in combination with other diabetes medicines or on its own in patients who cannot take metformin.
Estonian: Steglatrot võib kasutada kombinatsioonis teiste diabeediravimitega või ainsa ravimina patsientidel, kes ei saa võtta metformiini.
English: Other information about Steglatro
Estonian: Muu teave Steglatro kohta
English: What is Steglatro and what is it used for?
Estonian: Mis on Steglatro ja milleks seda kasutatakse?
English: A lower dose of ertugliflozin 5 mg was less effective.
Estonian: Ertugliflosiini 5 mg annus ei olnud nii efektiivne.
English: Steglatro contains the active substance ertugliflozin.
Estonian: Steglatro sisaldab toimeainet ertugliflosiini.
English: What are the risks associated with Steglatro?
Estonian: Mis riskid Steglatroga kaasnevad?
English: The studies looked mainly at effects on levels of HbA1c (a measure of blood glucose) after 6 months or one year of treatment.
Estonian: Uuringutes uuriti peamiselt toimet HbA1c (vere glükoosisisalduse näitaja) sisaldusele 6kuulise ja 1aastase ravi järel.
English: In addition, Steglatro can help some patients lose weight.
Estonian: Peale selle võib Steglatro mõnel patsiendil aidata langetada kehakaalu.
English: Steglatro is a medicine used to control blood glucose (sugar) levels in adults with type 2 diabetes together with diet and exercise.
Estonian: Steglatro on ravim, mida kasutatakse vere glükoosisisalduse (veresuhkru) reguleerimiseks II tüüpi diabeediga täiskasvanutel koos dieedi ja füüsilise koormusega.
English: Several studies in around 4,800 patients with type 2 diabetes have shown that ertugliflozin helps lower glucose levels on its own and in combination with other diabetes medicine.
Estonian: Mitmed uuringud ligikaudu 4800 II tüüpi diabeediga patsiendil on näidanud, et ertugliflosiin aitab vähendada vere glükoosisisaldust ainsa ravimina ning kombinatsioonis teiste diabeediravimitega.
English: For the full list of side effects and restrictions with Steglatro, see the package leaflet.
Estonian: Steglatro kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: It does this by blocking a protein in the kidneys (called SGLT2) that normally takes glucose back into the blood from the kidneys.
Estonian: Selleks blokeerib ravim neerudes leiduva valgu SGLT2, mis tavaliselt viib glükoosi neerudest tagasi verre.
English: How is Steglatro used?
Estonian: Kuidas Steglatrot kasutatakse?
English: HbA1c levels fell by 0.6 points with ertugliflozin and 0.7 points with glimepiride.
Estonian: HbA1c sisaldus vähenes ertugliflosiini rühmas 0,6 protsendipunkti ja glimepiriidi rühmas 0,7 protsendipunkti.
English: • A third study found that a combination of ertugliflozin at a 15 mg dose with metformin was about as effective as a combination of metformin with another diabetes medicine, glimepiride.
Estonian: • Kolmandas uuringus leiti, et ertugliflosiini 15 mg annuse kombinatsioon metformiiniga oli ligikaudu sama efektiivne nagu metformiini kombinatsioon teise diabeediravimi glimepiriidiga.
English: Finally, in addition to lowering glucose levels, studies showed that ertugliflozin can help patients reduce bodyweight.
Estonian: Lisaks näitasid uuringud, et peale vere glükoosisisalduse vähendamise aitas ertugliflosiin patsientidel langetada ka kehakaalu.
English: How does Steglatro work?
Estonian: Kuidas Steglatro toimib?
English: The active substance in Steglatro, ertugliflozin, helps to lower blood glucose by making the patient pass out glucose in the urine.
Estonian: Steglatro toimeaine ertugliflosiin aitab vähendada vere glükoosisisaldust, suurendades glükoosi eritumist uriiniga.
English: • A seventh study showed that ertugliflozin was not more effective than placebo in patients with moderate kidney impairment.
Estonian: • Seitsmendas uuringus tõendati, et ertugliflosiin ei olnud mõõduka neerufunktsiooni kahjustusega patsientidel platseebost efektiivsem.
English: An overview of Steglatro and why it is authorised in the EU
Estonian: Ülevaade ravimist Steglatro ja ELis müügiloa väljastamise põhjendus
English: Rare cases of diabetic ketoacidosis, a serious condition where the patient has very high blood acid levels, may occur in up to 1 in 1,000 patients.
Estonian: Harvadel juhtudel (kuni 1 patsiendil 1000st) võib esineda diabeetiline ketoatsidoos, mis on raske seisund, mille korral patsiendi vere happesisaldus on väga suur.
English: Studies showed that Steglatro helps lower glucose levels on its own and in combination with other diabetes medicines.
Estonian: Uuringutes tõendati, et Steglatro aitab vähendada vere glükoosisisaldust ainsa ravimina ja kombinatsioonis teiste diabeediravimitega.
English: • A fifth study found that adding ertugliflozin to a combination of sitagliptin and metformin was more effective than placebo.
Estonian: • Viiendas uuringus leiti, et ertugliflosiini lisamine sitagliptiini ja metformiini kombinatsioonile oli efektiivsem kui platseebo lisamine.
English: What benefits of Steglatro have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Steglatro kasulikkus?
English: • A second study found that in patients taking a combination of ertugliflozin and metformin, HbA1c levels fell by around 0.8 points, compared with reductions of 0.03 when placebo was added to metformin.
Estonian: • Teises uuringus leiti, et ertugliflosiini ja metformiini kombinatsiooni kasutanud patsientidel vähenes HbA1c sisaldus ligikaudu 0,8 protsendipunkti, samas kui platseebo lisamisel metformiinile vähenes HbA1c sisaldus 0,03 protsendipunkti.
English: Steglatro can only be obtained with a prescription.
Estonian: Steglatro on retseptiravim.
English: • A study of ertugliflozin on its own, showed that levels of HbA1c (a measure of blood glucose) fell by between 0.8 points and 1 point in patients who took the medicine compared with a rise of 0.2 points in patients receiving placebo (a dummy treatment).
Estonian: • Ainsa ravimina manustatud ertugliflosiini uuringus leiti, et HbA1c (vere glükoosisisalduse näitaja) sisaldus vähenes ravimit kasutanud patsientidel 0,8-1 protsendipunkti, samas kui platseebot (näivat ravimit) kasutanud patsientidel HbA1c sisaldus suurenes 0,2 protsendipunkti.
English: HbA1c levels fell by between 0.8 and 0.9 points when ertugliflozin was added, compared with a fall of 0.1 with placebo.
Estonian: Ertugliflosiini lisamisel vähenes HbA1c sisaldus ligikaudu 0,80,9 protsendipunkti, samas kui platseebo lisamisel vähenes HbA1c sisaldus 0,1 protsendipunkti.
English: HbA1c levels fell by a further 0.5 points when both medicines were added to metformin.
Estonian: Mõlema ravimi lisamisel metformiinile vähenes HbA1c sisaldus veel 0,5 protsendipunkti.
English: • A fourth study found that, in patients taking metformin, adding ertugliflozin was as effective as adding sitagliptin, another diabetes medicine, with HbA1c levels falling by around 1 point with both treatments.
Estonian: • Neljandas uuringus leiti, et metformiini kasutavatel patsientidel oli ertugliflosiini lisamine sama efektiivne nagu teise diabeediravimi sitagliptiini lisamine.
English: • A sixth study found that adding the combination of ertugliflozin and sitagliptin to diet and exercise was much more effective than placebo, with HbA1c levels falling by between 1.6 and 1.7 points with the combination of ertugliflozin and sitagliptin compared with a fall of 0.4 points with placebo.
Estonian: Ertugliflosiini ja sitagliptiini kombinatsiooni lisamisel vähenes HbA1c sisaldus 1,6-1,7 protsendipunkti, samas kui platseebo lisamisel vähenes HbA1c sisaldus 0,4 protsendipunkti.
English: Nausea is more common in women than in men.
Estonian: Iiveldus on sagedam naistel kui meestel.
English: What measures are being taken to ensure the safe and effective use of Xyrem?
Estonian: Mis meetmed võetakse, et tagada Xyremi ohutu ja efektiivne kasutamine?
English: The European Commission granted a marketing authorisation valid throughout the European Union for Xyrem on 13 October 2005.
Estonian: Euroopa Komisjon andis Xyremi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 13. oktoobril 2005.
English: Both doses should be prepared at the same time before the patient goes to bed.
Estonian: Mõlemad annused tuleb valmistada samal ajal, enne patsiendi magamaminekut.
English: The full EPAR for Xyrem can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Xyremi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: The second dose is taken 2.5 to 4 hours later.
Estonian: Teine annus võetakse 2,5-4 tundi hiljem.
English: A risk management plan has been developed to ensure that Xyrem is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Xyremi võimalikult ohutu kasutamine.
English: Xyrem can also cause respiratory depression (inhibition of breathing).
Estonian: Xyrem võib tekitada ka respiratoorset depressiooni (hingamispeetust).
English: This improves the symptoms of narcolepsy.
Estonian: See leevendab narkolepsia sümptomeid.
English: The first dose of the day is taken at bedtime, at least two to three hours after food.
Estonian: Ööpäeva esimene annus võetakse magamaminekul, vähemalt 2-3 tundi pärast sööki.
English: Patients taking Xyrem should avoid alcohol, as it can increase Xyrem's effects.
Estonian: Xyremit võtvad patsiendid peavad vältima alkoholi tarvitamist, sest see võib suurendada Xyremi mõju.
English: The data obtained in the fibromyalgia studies did not support the use of Xyrem in this condition in the European population.
Estonian: Fibromüalgia uuringute andmed ei toetanud Xyremi kasutamist Euroopa elanikkonnas selle haiguse raviks.
English: Although the 9-g dose was the most effective, it was linked to high levels of side effects, so the Committee recommended a starting dose of 4.5 g per day.
Estonian: Kuigi annus 9 g oli efektiivseim, seostus sellega rohkesti kõrvalnähte, mille tõttu soovitas komitee algannust 4,5 g ööpäevas.
English: The main measure of effectiveness was based on reduction of pain severity and improvement in function.
Estonian: Efektiivsuse põhinäitaja oli valu tugevuse vähenemine ja talitluse paranemine.
English: Xyrem was more effective than placebo in reducing symptoms.
Estonian: Xyrem oli sümptomite vähendamisel efektiivsem kui platseebo.
English: The effects of Xyrem have also been studied in fibromyalgia patients with moderate to severe symptoms in two short-term (12-week) studies in 1,121 patients, and one long-term (up to nine months) study in 560 patients.
Estonian: Xyremi mõju uuriti ka fibromüalgia mõõdukate kuni raskete sümptomitega patsientidel kahes lühiajalises (12-nädalases) uuringus (1121 patsienti) ja ühes pikaajalises (kuni 9 kuud) uuringus (560 patsienti).
English: The CHMP decided that Xyrem's benefits are greater than its risks.
Estonian: Inimravimite komitee otsustas, et Xyremi kasulikkus ületab kaasnevaid riske.
English: Fibromyalgia is a disease of unknown origin causing long-lasting, widespread pain and painful responses to touch.
Estonian: Fibromüalgia (pehmekoereuma) on teadmata põhjusega haigus, mis tekitab kauakestva ja laiaulatusliku valu ja valuliku reaktsiooni puudutusele.
English: The precise way in which it works is not known, but it is thought to attach to receptor molecules on the surface of some cells in the brain.
Estonian: Täpne toimemehhanism ei ole teada, kuid oletatakse, et aine seondub aju teatud närvirakkude pinnal olevate retseptoritega.
English: The main measure of effectiveness was the change in daytime sleepiness.
Estonian: Efektiivsuse põhinäitaja oli päevase unisuse muutumine.
English: Xyrem must not be used in patients with major depression, in patients with ‘succinic semialdehyde dehydrogenase deficiency' (a rare metabolic disease), or in patients being treated with opioids (such as some painkillers) or barbiturates (such as some anaesthetics and medicines used to prevent seizures).
Estonian: Xyremit ei tohi kasutada patsiendid, kellel on raske depressioon, suktsiinhappe semialdehüüdi dehüdrogenaasi vaegus (SSADHD, haruldane ainevahetushaigus) ega patsiendid, kes saavad opioide (nt teatud valuvaigistid) või barbituraate (nt teatud anesteetikumid ja epilepsiaravimid).
English: The study measured the number of cataplexy attacks over two weeks.
Estonian: Uuringus jälgiti katapleksiaepisoodide arvu kahe nädala jooksul.
English: Narcolepsy is a sleep disorder that causes excessive daytime sleepiness.
Estonian: Narkolepsia on unehäire, mis põhjustab liigset päevast unisust.
English: The dose is then adjusted at one- to two-week intervals depending on the patient's response.
Estonian: Seejärel korrigeeritakse annust ühe kuni kahe nädala tagant, olenevalt patsiendi ravivastusest.
English: Xyrem is given at a dose of 4.5 to 9 g per day in two equally divided doses.
Estonian: Xyremit võetakse 4,5-9 g ööpäevas, mis jagatakse kaheks võrdseks annuseks.
English: This document is a summary of the European Public Assessment Report (EPAR) for Xyrem.
Estonian: See on ravimi Xyrem Euroopa avaliku hindamisaruande kokkuvõte.
English: Patients who have problems with their kidneys should consider a low sodium diet.
Estonian: Neeruprobleemidega patsiendid peavad kaaluma väikese naatriumisisaldusega dieeti.
English: Xyrem is an oral solution that contains the active substance sodium oxybate (500 mg/ml).
Estonian: Xyrem on suukaudne lahus, mis sisaldab toimeainena naatriumoksübaati (500 mg/ml).
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Xyrem.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: The most common side effects with Xyrem (seen in more than 1 patient in 10) are dizziness, headache and nausea (feeling sick).
Estonian: Xyremi kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on peapööritus, peavalu ja iiveldus.
English: What is Xyrem?
Estonian: Mis on Xyrem?
English: The Committee recommended that Xyrem be given marketing authorisation.
Estonian: Komitee soovitas anda Xyremi müügiloa.
English: For more information about treatment with Xyrem, read the Package Leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Xyremiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Other information about Xyrem:
Estonian: Muu teave Xyremi kohta
English: Cataplexy is a symptom of narcolepsy involving sudden muscle weakness in response to an emotional reaction such as anger, fear, joy, laughter or surprise.
Estonian: Katapleksia on narkolepsia sümptom, kus emotsionaalse reaktsiooni, näiteks viha, hirmu, rõõmu, naeru või üllatuse korral esineb äkilist lihasnõrkust.
English: The effects of Xyrem in narcolepsy and cataplexy have been studied in 707 patients in four studies.
Estonian: Xyremi toimet narkolepsia ja katapleksia korral uuriti neljas uuringus, milles osales 707 patsienti.
English: When taken at bedtime, Xyrem increases deep sleep and increases the amount of time spent asleep at night, whilst reducing the number of sleeping periods during the day.
Estonian: Magamaminekul võetud Xyrem soodustab süvaund ja pikendab öist uneaega ning samas vähendab päevaseid uneepisoode.
English: Xyrem also reduced excessive daytime sleepiness in patients who continued to take modafinil, as well as in those who took Xyrem alone.
Estonian: Xyrem vähendas ka liigset päevast unisust patsientidel, kes jätkasid modafiniili võtmist, samuti nendel, kes võtsid Xyremit ainsa ravimina.
English: Before taking the medicine, the patient should dissolve the dose in water to make up a drink.
Estonian: Enne ravimi võtmist peab patsient annuse lahustama vees, nii et tekib joodav lahus.
English: In the first study, a daily dose of 9 g reduced the number of cataplexy attacks by 16.1 (from 23.5 to 8.7) per week, compared with a fall of 4.3 per week in the patients taking placebo.
Estonian: Esimeses uuringus vähenes ööpäevase annuse 9 g korral katapleksiaepisoodide arv nädalas 16,1 võrra (väärtuselt 23,5 väärtusele 8,7); platseebo korral vähenes episoodide arv nädalas 4,3 võrra.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Xyrem, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Xyremi omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: Why has Xyrem been approved?
Estonian: Miks Xyrem heaks kiideti?
English: Xyrem sodium oxybate
Estonian: Xyrem naatriumoksübaat
English: In all of the studies, Xyrem was given at a daily dose between 3 and 9 g and was compared with placebo (a dummy treatment).
Estonian: Kõigis uuringuis manustati Xyremit annuses 3-9 g ööpäevas ja võrreldi selle toimet platseebo (näiva ravimi) toimega.
English: Cataplexy can sometimes cause a patient to collapse.
Estonian: Katapleksia korral võib patsient mõnikord kokku kukkuda.
English: The company that makes Xyrem will minimise the risk of abuse of Xyrem by providing educational materials to healthcare workers and patients, strictly controlling the distribution of the medicine, and monitoring its use.
Estonian: Xyremi tootja vähendab Xyremi väärkasutamise riski sellega, et annab tervishoiutöötajatele ja patsientidele teabematerjale, piirab rangelt ravimi müüki ja jälgib ravimi kasutamist.
English: Since the effective dose is close to the dose at which side effects become serious, increases in dose must be carried out strictly and under the supervision of a doctor specialised in the treatment of sleep disorders.
Estonian: Et efektiivne annus on lähedal annusele, mis võib põhjustada raskeid kõrvalnähte, peab annust suurendama ettevaatlikult ja unehäirete ravile spetsialiseerunud arsti järelevalve all.
English: The second study showed that Xyrem continued to prevent cataplexy attacks after long-term treatment: there was no change over two weeks in the number of attacks in the patients continuing to take Xyrem, compared to an increase of 21.0 attacks in those switching to placebo.
Estonian: Teine uuring näitas, et Xyremi toime katapleksiaepisoodide ennetamisel pikaajalise ravi korral püsis: kahe nädala jooksul ei muutunud episoodide arv patsientidel, kes jätkasid Xyremi võtmist, kuid platseebot manustama hakanud patsientidel suurenes episoodide arv 21,0 võrra.